X-ray crystal structure of ERK5 (MAPK7) in complex with a specific inhibitor

Journal of Medicinal Chemistry

Volumn 56, Issue 11, 2013, Pages 4413-4421

  Elkins, Jonathan M ^a   Wang, Jing ^a   Deng, Xianming ^b   Pattison, Michael J ^c   Arthur, J Simon C ^c   Erazo, Tatiana ^d   Gomez, Nestor ^d   Lizcano, Jose M ^d   Gray, Nathanael S ^b   Knapp, Stefan ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

^d INSTITUT DE NEUROCIÈNCIES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE;

ARTICLE; BINDING SITE; CRYSTAL STRUCTURE; CRYSTALLIZATION; HUMAN; WESTERN BLOTTING;

AMINO ACID SEQUENCE; AZEPINES; CRYSTALLOGRAPHY, X-RAY; HEK293 CELLS; HELA CELLS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 7; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN CONFORMATION; PYRIMIDINES; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 84879039565     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm4000837     Document Type: Article

References (46)

1. Zhou, G.; Bao, Z. Q.; Dixon, J. E. Components of a new human protein kinase signal transduction pathway J. Biol. Chem. 1995, 270, 12665-12669
2. Lee, J. D.; Ulevitch, R. J.; Han, J. Primary structure of BMK1: a new mammalian map kinase Biochem. Biophys. Res. Commun. 1995, 213, 715-724
3. Sohn, S. J.; Sarvis, B. K.; Cado, D.; Winoto, A. ERK5MAPK regulates embryonic angiogenesis and acts as a hypoxia-sensitive repressor of vascular endothelial growth factor expression J. Biol. Chem. 2002, 277, 43344-43351 (Pubitemid 35285722)
4. Regan, C. P.; Li, W.; Boucher, D. M.; Spatz, S.; Su, M. S.; Kuida, K. Erk5 null mice display multiple extraembryonic vascular and embryonic cardiovascular defects Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 9248-9253 (Pubitemid 34764599)
5. Yan, L.; Carr, J.; Ashby, P. R.; Murry-Tait, V.; Thompson, C.; Arthur, J. S. C. Knockout of ERK5 causes multiple defects in placental and embryonic development BMC Dev. Biol. 2003, 3, 11
6. Nishimoto, S.; Kusakabe, M.; Nishida, E. Requirement of the MEK5-ERK5 pathway for neural differentiation in Xenopus embryonic development EMBO Rep. 2005, 6, 1064-1069 (Pubitemid 41637652)
7. Zou, J.; Pan, Y.-W.; Wang, Z.; Chang, S.-Y.; Wang, W.; Wang, X.; Tournier, C.; Storm, D. R.; Xia, Z. Targeted deletion of ERK5MAP kinase in the developing nervous system impairs development of GABAergic interneurons in the main olfactory bulb and behavioral discrimination between structurally similar odorants J. Neurosci. 2012, 32, 4118-4132
8. Kato, Y.; Tapping, R. I.; Huang, S.; Watson, M. H.; Ulevitch, R. J.; Lee, J. D. Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor Nature 1998, 395, 713-716 (Pubitemid 28475970)
9. Buschbeck, M.; Ullrich, A. The unique C-terminal tail of the mitogen-activated protein kinase ERK5 regulates its activation and nuclear shuttling J. Biol. Chem. 2005, 280, 2659-2067
10. Terasawa, K.; Okazaki, K.; Nishida, E. Regulation of c-Fos and Fra-1 by the MEK5-ERK5 pathway Genes Cells 2003, 8, 263-273 (Pubitemid 36511707)
11. Kamakura, S.; Moriguchi, T.; Nishida, E. Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus J. Biol. Chem. 1999, 274, 26563-26571
12. Yang, C. C.; Ornatsky, O. I.; McDermott, J. C.; Cruz, T. F.; Prody, C. A. Interaction of myocyte enhancer factor 2 (MEF2) with a mitogen-activated protein kinase, ERK5/BMK1 Nucleic Acids. Res. 1998, 26, 4771-4777 (Pubitemid 28466627)
13. Kato, Y.; Kravchenko, V. V; Tapping, R. I.; Han, J.; Ulevitch, R. J.; Lee, J. D. BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C EMBO J. 1997, 16, 7054-7066 (Pubitemid 27520805)
14. English, J. M.; Pearson, G.; Baer, R.; Cobb, M. H. Identification of substrates and regulators of the mitogen-activated protein kinase ERK5 using chimeric protein kinases J. Biol. Chem. 1998, 273, 3854-3860 (Pubitemid 28103240)
15. Kasler, H. G.; Victoria, J.; Duramad, O.; Winoto, A. ERK5 is a novel type of mitogen-activated protein kinase containing a transcriptional activation domain Mol. Cell. Biol. 2000, 20, 8382-8389
16. Morimoto, H.; Kondoh, K.; Nishimoto, S.; Terasawa, K.; Nishida, E. Activation of a C-terminal transcriptional activation domain of ERK5 by autophosphorylation J. Biol. Chem. 2007, 282, 35449-35456 (Pubitemid 350277147)
17. Yan, C.; Luo, H.; Lee, J. D.; Abe, J.; Berk, B. C. Molecular cloning of mouse ERK5/BMK1 splice variants and characterization of ERK5 functional domains J. Biol. Chem. 2001, 276, 10870-10878 (Pubitemid 38089264)
18. Kinoshita, T.; Yoshida, I.; Nakae, S.; Okita, K.; Gouda, M.; Matsubara, M.; Yokota, K.; Ishiguro, H.; Tada, T. Crystal structure of human mono-phosphorylated ERK1 at Tyr204 Biochem. Biophys. Res. Commun. 2008, 377, 1123-1127
19. Canagarajah, B. J.; Khokhlatchev, A.; Cobb, M. H.; Goldsmith, E. J. Activation mechanism of the MAP kinase ERK2 by dual phosphorylation Cell 1997, 90, 859-869 (Pubitemid 27381625)
20. Déléris, P.; Trost, M.; Topisirovic, I.; Tanguay, P.-L.; Borden, K. L. B.; Thibault, P.; Meloche, S. Activation loop phosphorylation of ERK3/ERK4 by group I p21-activated kinases (PAKs) defines a novel PAK-ERK3/4-MAPK-activated protein kinase 5 signaling pathway J. Biol. Chem. 2011, 286, 6470-6478
21. Mody, N.; Campbell, D. G.; Morrice, N.; Peggie, M.; Cohen, P. An analysis of the phosphorylation and activation of extracellular-signal-regulated protein kinase 5 (ERK5) by mitogen-activated protein kinase kinase 5 (MKK5) in vitro Biochem. J. 2003, 372, 567-575 (Pubitemid 36723902)
22. McCracken, S. R. C.; Ramsay, A.; Heer, R.; Mathers, M. E.; Jenkins, B. L.; Edwards, J.; Robson, C. N.; Marquez, R.; Cohen, P.; Leung, H. Y. Aberrant expression of extracellular signal-regulated kinase 5 in human prostate cancer Oncogene 2008, 27, 2978-2988 (Pubitemid 351668010)
23. Lochhead, P. A.; Gilley, R.; Cook, S. J. ERK5 and its role in tumour development Biochem. Soc. Trans. 2012, 40, 251-256
24. Hsieh, F. C.; Cheng, G.; Lin, J. Evaluation of potential Stat3-regulated genes in human breast cancer Biochem. Biophys. Res. Commun. 2005, 335, 292-299 (Pubitemid 41140220)
25. Montero, J. C.; Ocana, A.; Abad, M.; Ortiz-Ruiz, M. J.; Pandiella, A.; Esparis-Ogando, A. Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target PLoS One 2009, 4, e5565
26. Mehta, P. B.; Jenkins, B. L.; McCarthy, L.; Thilak, L.; Robson, C. N.; Neal, D. E.; Leung, H. Y. MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion Oncogene 2003, 22, 1381-1389 (Pubitemid 36384600)
27. Sticht, C.; Freier, K.; Knopfle, K.; Flechtenmacher, C.; Pungs, S.; Hofele, C.; Hahn, M.; Joos, S.; Lichter, P. Activation of MAP kinase signaling through ERK5 but not ERK1 expression is associated with lymph node metastases in oral squamous cell carcinoma (OSCC) Neoplasia 2008, 10, 462-470 (Pubitemid 351657388)
28. Zen, K.; Yasui, K.; Nakajima, T.; Zen, Y.; Zen, K.; Gen, Y.; Mitsuyoshi, H.; Minami, M.; Mitsufuji, S.; Tanaka, S.; Itoh, Y.; Nakanuma, Y.; Taniwaki, M.; Arii, S.; Okanoue, T.; Yoshikawa, T. ERK5 is a target for gene amplification at 17p11 and promotes cell growth in hepatocellular carcinoma by regulating mitotic entry Genes, Chromosomes Cancer 2009, 48, 109-120
29. Hayashi, M.; Kim, S. W.; Imanaka-Yoshida, K.; Yoshida, T.; Abel, E. D.; Eliceiri, B.; Yang, Y.; Ulevitch, R. J.; Lee, J. D. Targeted deletion of BMK1/ERK5 in adult mice perturbs vascular integrity and leads to endothelial failure J. Clin. Invest. 2004, 113, 1138-1148 (Pubitemid 38544099)
30. Hayashi, M.; Lee, J. D. Role of the BMK1/ERK5 signaling pathway: lessons from knockout mice J. Mol. Med. (Berlin) 2004, 82, 800-808
31. Deng, X.; Dzamko, N.; Prescott, A.; Davies, P.; Liu, Q.; Yang, Q.; Lee, J. D.; Patricelli, M. P.; Nomanbhoy, T. K.; Alessi, D. R.; Gray, N. S. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2 Nat. Chem. Biol. 2011, 7, 203-205
32. Kwiatkowski, N.; Jelluma, N.; Filippakopoulos, P.; Soundararajan, M.; Manak, M. S.; Kwon, M.; Choi, H. G.; Sim, T.; Deveraux, Q. L.; Rottmann, S.; Pellman, D.; Shah, J. V; Kops, G. J. P. L.; Knapp, S.; Gray, N. S. Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function Nat. Chem. Biol. 2010, 6, 359-368
33. Liu, S.; Sun, J.-P.; Zhou, B.; Zhang, Z.-Y. Structural basis of docking interactions between ERK2 and MAP kinase phosphatase 3 Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 5326-5331
34. Deng, X.; Yang, Q.; Kwiatkowski, N.; Sim, T.; McDermott, U.; Settleman, J. E.; Lee, J. D.; Gray, N. S. Discovery of a benzo[ e ]pyrimido-[5,4- b ][1,4]diazepin-6(11 H)-one as a potent and selective inhibitor of big MAP kinase 1 ACS Med. Chem. Lett. 2011, 2, 195-200
35. Tatake, R. J.; O'Neill, M. M.; Kennedy, C. A.; Wayne, A. L.; Jakes, S.; Wu, D.; Kugler, S. Z.; Kashem, M. A.; Kaplita, P.; Snow, R. J. Identification of pharmacological inhibitors of the MEK5/ERK5 pathway Biochem. Biophys. Res. Commun. 2008, 377, 120-125
36. Savitsky, P.; Bray, J.; Cooper, C. D. O.; Marsden, B. D.; Mahajan, P.; Burgess-Brown, N. A.; Gileadi, O. High-throughput production of human proteins for crystallization: the SGC experience J. Struct. Biol. 2010, 172, 3-13
37. Leslie, A. G. W.; Powell, H. R. Processing diffraction data with Mosflm Evol. Methods Macromol. Crystallogr. 2007, 245, 41-51
38. Evans, P. R. An introduction to data reduction: space-group determination, scaling and intensity statistics Acta Crystallogr. 2011, D67, 282-292
39. McCoy, A. J.; Grosse-Kunstleve, R. W.; Adams, P. D.; Winn, M. D.; Storoni, L. C.; Read, R. J. Phaser crystallographic software J. Appl. Crystallogr. 2007, 40, 658-674 (Pubitemid 47080256)
40. Patel, S. B.; Cameron, P. M.; O'Keefe, S. J.; Frantz-Wattley, B.; Thompson, J.; O'Neill, E. A.; Tennis, T.; Liu, L.; Becker, J. W.; Scapin, G. The three-dimensional structure of MAP kinase p38beta: different features of the ATP-binding site in p38beta compared with p38alpha Acta Crystallogr. 2009, D65, 777-785
41. Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K. Features and development of Coot Acta Crystallogr. 2010, D66, 486-501
42. Murshudov, G. N.; Skubák, P.; Lebedev, A. A.; Pannu, N. S.; Steiner, R. A.; Nicholls, R. A.; Winn, M. D.; Long, F.; Vagin, A. A. REFMAC5 for the refinement of macromolecular crystal structures Acta Crystallogr. 2011, D67, 355-367
43. Schüttelkopf, A. W.; Van Aalten, D. M. F. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes Acta Crystallogr. 2004, D60, 1355-1363 (Pubitemid 41079731)
44. Chen, V. B.; Arendall, W. B.; Headd, J. J.; Keedy, D. A.; Immormino, R. M.; Kapral, G. J.; Murray, L. W.; Richardson, J. S.; Richardson, D. C. MolProbity: all-atom structure validation for macromolecular crystallography Acta Crystallogr. 2010, D66, 12-21
45. Iñesta-Vaquera, F. A.; Campbell, D. G.; Tournier, C.; Gómez, N.; Lizcano, J. M.; Cuenda, A. Alternative ERK5 regulation by phosphorylation during the cell cycle Cell. Signalling 2010, 22, 1829-1837
46. Deng, X.; Elkins, J.; Zhang, J.; Yang, Q.; Choi, H. G.; Dzamko, N.; Lee, J.-D.; Sim, T.; Kim, N.; Knapp, S.; Alessi, D. R.; Gray, N. S. Structure determinants for big MAP kinase 1 and leucine rich repeat kinase 2 activities of benzo[ e ]pyrimido[5,4- b ]diazepine-6(11 H)-ones. J. Med. Chem., manuscript submitted.